K
Kynexis
Biotech & Life Sciences · Naarden, Netherlands · Founded 2023
Precision therapeutics for cognitive impairment in schizophrenia MoreLess
Kynexis is a clinical-stage biotechnology company developing precision therapeutics for cognitive disorders, with lead candidate KYN-5356, a selective oral KAT-II (kynurenine aminotransferase II) inhibitor licensed from Mitsubishi Tanabe Pharma for cognitive impairment associated with schizophrenia (CIAS) and potential expansion into Alzheimer’s and other cognitive diseases. Founded in 2023 and headquartered in Naarden, Netherlands, with a US subsidiary in Cambridge, Massachusetts, it builds on research by scientific co-founders Dr Robert Schwarcz and Dr Carol Tamminga and is led by CEO Kees Been. After an initial €57 million Series A in 2023 led by Forbion, Ysios Capital and Sunstone Life Science Ventures, Kynexis in August 2026 closed a €40 million Series A extension led by Novartis Venture Fund with Forbion, Ysios and Sunstone returning—bringing total Series A financing to €97 million ($110 million)—to close out Phase 2 CIAS activities and prepare registrational development. Sources: company 19 Aug 2026; Forbion / PharmaLetter Aug 2026.
Talent graph
Kynexis's talent
Source: Dealroom Talent Intelligence.
Investors
3 investors on Kynexis's cap table
Sourced from Dealroom's funding history.
Global footprint
Where Kynexis has talent and traffic
team presence
Market sentiment
What the market is saying about Kynexis
An AI-synthesized read of the highest-engagement posts about Kynexis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kynexis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.